Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Nasopharyngeal Carcinoma 20Carcinoma, Non-Small-Cell Lung 18Esophageal Squamous Cell Carcinoma 15Breast Neoplasms 14Triple Negative Breast Neoplasms 13Squamous Cell Carcinoma of Head and Neck 11Carcinoma, Hepatocellular 11Stomach Neoplasms 8Small Cell Lung Carcinoma 8Uterine Cervical Neoplasms 6Recurrence 6Head and Neck Neoplasms 6Colorectal Neoplasms 6Carcinoma, Transitional Cell 5Carcinoma, Renal Cell 5Urinary Bladder Neoplasms 4Sarcoma 4Rectal Neoplasms 4Neoplasm Metastasis 4Melanoma 4Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4Locally Advanced Rectal Cancer 3Liver Neoplasms 3Turcot syndrome 2Pathologic Complete Response 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Nasopharyngeal Neoplasms 2

Interventions

toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Muscle-invasive Bladder Urothelial Carcinoma × toripalimab × Clear all
NCT07279597 2025-12-19

A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer

Tongji Hospital

Phase 2 Not yet recruiting
45 enrolled
Genitourinary

Muscle-invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡